logo-loader
viewZynerba Pharmaceuticals

Zynerba updates on its two clinical CBD studies

Zynerba Pharmaceuticals (NASDAQ:ZYNE) CEO Armando Anido caught up with Proactive Investors at the BIO CEO & Investor Conference in New York. 

Anido says the company is on track to report results from CONNECT-FX, its clinical study of CBD in children and adolescents with Fragile X Syndrome in the second half of 2019. It has completed enrollment in its Phase 2 BELIEVE 1 of ZYN002 to treat epileptic encephalopathy, with top-line results will be reported in the third quarter of 2019.

Quick facts: Zynerba Pharmaceuticals

Price: 3.96 USD

NASDAQ:ZYNE
Market: NASDAQ
Market Cap: $115.85 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Zynerba Pharmaceuticals named herein, including the promotion by the Company of Zynerba Pharmaceuticals in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Seneca Global Income & Growth's David Thomas reckons there's much more NAV...

Seneca Global Income & Growth Trust PLC's (LON:SIGT) David Thomas tells Proactive London's Andrew Scott it's a multi-asset trust and, unusually in the space, he says they're value-investors. ''At the moment we've got around 60% equities of which over half is in the UK'', he says. ''In the UK...

9 hours, 30 minutes ago

2 min read